Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2025), Nat Commun, 16
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M. et al, (2025), Cell Genom, 5
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.
Greene J. et al, (2025), Cancer Control, 32
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Javed SR. et al, (2024), Br J Cancer
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43
New role of fat-free mass in cancer risk linked with genetic predisposition.
Harris BHL. et al, (2024), Sci Rep, 14
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
Clift AK. et al, (2023), Lancet Digit Health, 5, e571 - e581
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2023), Nat Commun, 14
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br J Cancer
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), BMJ Support Palliat Care
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Charles Coombes R. et al, (2023), Nat Commun, 14
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7
Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.
Clift AK. et al, (2023), BMJ, 381
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
Lord SR. and Harris AL., (2023), Br J Cancer, 128, 958 - 966
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2023)
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2023)
Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2023)